Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium
Armelle Duquenne
N. Brison
I. Parijs
Angelica Pagliazzi
M. Baetens
Bettina Blaumeiser
M. Bruneau
Saskia Bulk
B. Callewaert
S. Coppens
Michelle Deberg
A. de Leener
M. De Rademaeker
J. Désir
K. Devriendt
A. Fieuw
J. Gatot
M. Jamar
S. Janssens
L. Lannoo
A. Marichal
Björn Menten
Colombine Meunier
B. Pichon
S. Rombout
Ileen Slegers
Yves Sznajer
O. Vanakker
K. van Berkel
L. Vancoillie
A. van den Bogaert
I. Vandernoot
K. Van Den Bogaert
J. Vermeesch
Katrien Janssens
Medicine
Abstract
Prenatal cell‐free DNA screening is widely used to assess the risk of fetal trisomy 21, 18, and 13. Although commercial and laboratory‐developed tests (LDTs) show high accuracy in validation studies, real‐world longitudinal performance data are lacking.